(Z)-1-acetyl-3-thiophen-2yl-methylene-piperazine-2,5-dione | 171888-26-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Z)-1-acetyl-3-thiophen-2yl-methylene-piperazine-2,5-dione
• 英文别名: (3Z)-1-Acetyl-3-(2-thenylidene)-2,5-piperazinedione；(3Z)-1-acetyl-3-(thiophen-2-ylmethylidene)piperazine-2,5-dione
• CAS: 171888-26-9
• 化学式: C₁₁H₁₀N₂O₃S
• 分子量: 250.278
• InChiKey: OTFAGYBUTGLAFS-UITAMQMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  94.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (Z)-1-acetyl-3-thiophen-2yl-methylene-piperazine-2,5-dione 在 盐酸 、 水 作用下， 反应 4.0h， 以48%的产率得到3-(2-thienyl)-2-oxopropionic acid
  参考文献：
  名称：

  Novel approach to the synthesis of aliphatic and aromatic α-keto acids

  摘要：

  A new practical and efficient synthesis of alpha-keto acids was accomplished starting from the synthon 1,4-diacetylpiperazine-2,5-dione. The synthesis encompasses both aromatic and aliphatic substrates proving to be versatile and innovative with excellent carbon economy and recycling of the glycine by-product. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.06.078
• 作为产物：
  描述：

  (E)-1-acetyl-3-(thiophen-2-ylmethylene)piperazine-2,5-dione 以 二氯甲烷 为溶剂， 生成 (Z)-1-acetyl-3-thiophen-2yl-methylene-piperazine-2,5-dione
  参考文献：
  名称：

  杂环半哌嗪：水相容性肽衍生光电开关

  摘要：

  存在水的光开关：用亚杂芳基取代基修饰环状二肽产生新型生物相容性分子光开关。它们显示出高热稳定性，并且可以在含水条件下与有机助溶剂一起使用。扩展的杂芳烃系统可实现可见光的双向切换。

  DOI：

  10.1002/chem.202204009

文献信息

• Pharmaceutical compounds
  申请人：Xenova Limited

  公开号：US05891877A1

  公开（公告）日：1999-04-06

  Diketopiperazines of the formula ##STR1## where one or both of R.sub.1 and R.sub.2, which are different, are chosen from X and a phenyl group substituted by X, C(O)X, OC(O)CH.sub.2 X, OCH.sub.2 CH.sub.2 X, CH.sub.2 X, CONH(CH.sub.2).sub.n X, O(CH.sub.2).sub.n CH(OH)(CH.sub.2).sub.n X ##STR2## and, where appropriate, the other of R.sub.1 and R.sub.2 is a phenyl group optionally substituted by one or more groups selected from halogen, nitro, methoxy, NHC(O)R.sub.12, CO.sub.2 H, O(CH.sub.2).sub.n N(R.sub.12 R.sub.13), C.sub.1 -C.sub.4 alkyl and (CH.sub.2).sub.n C(O)OR.sub.12 ; X is a five- or six-membered heterocyclic ring selected from the group consisting of pyridyl, imidazolyl, furyl, pyrrolyl, pyrrolidinyl, thienyl, piperazinyl, piperidinyl, morpholinyl, quinolyl, isoquinotyl and indolyl, the heteroatom(s) of the said heterocyclic ring, when nitrogen, being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl, or SO.sub.2 Me, the heterocyclic ring being optionally substituted by halogen \x9bhydrogen!, methyl, MeS, phenyl, O(CH.sub.2).sub.n N(R.sub.12 R.sub.13) or optionally containing one or more carbonyl groups and being optionally fused to a benzene ring; Y is O or S; R.sub.12 and R.sub.13, which may be the same or different, are hydrogen or C.sub.1 -C.sub.6 alkyl; and n is 0 or an integer having the value 1, 2, 3 or 4; a pharmaceutically acceptable salts or esters having activity as inhibitors of plasminogen activator inhibitor.

  式子为##STR1##的二酮哌嗪，其中R.sub.1和R.sub.2中至少一个且不相同的基团选自X和被X取代的苯基团、C(O)X、OC(O)CH.sub.2 X、OCH.sub.2 CH.sub.2 X、CH.sub.2 X、CONH(CH.sub.2).sub.n X、O(CH.sub.2).sub.n CH(OH)(CH.sub.2).sub.n X ##STR2## ，如适用，R.sub.1和R.sub.2中的另一个基团是一个苯基团，可选地被一个或多个来自卤素、硝基、甲氧基、NHC(O)R.sub.12、CO.sub.2 H、O(CH.sub.2).sub.n N(R.sub.12 R.sub.13)、C.sub.1-C.sub.4烷基和(CH.sub.2).sub.n C(O)OR.sub.12的基团取代；X是选自吡啶基、咪唑基、呋喃基、吡咯基、吡咯啉基、噻吩基、哌嗪基、哌啶基、吗啉基、喹啉基、异喹啉基和吲哚基的五元或六元杂环环，当氮为杂原子时，可选地被氢、甲基、氧、叔丁氧羰基或SO.sub.2Me取代，该杂环环可选地被卤素\x9b氢！、甲基、MeS、苯基、O(CH.sub.2).sub.n N(R.sub.12 R.sub.13)或可选地含有一个或多个羰基基团并可选地与苯环融合；Y为O或S；R.sub.12和R.sub.13，可以相同也可以不同，是氢或C.sub.1-C.sub.6烷基；n为0或具有值1、2、3或4的整数；具有抑制纤溶酶原激活因子抑制剂活性的药学上可接受的盐或酯。
• Fused benzeneoxyacetic acid derivatives as PGl2 receptor agonists
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0542203B1

  公开（公告）日：1996-07-03
• PHARMACEUTICAL PIPERAZINE COMPOUNDS
  申请人：XENOVA LIMITED

  公开号：EP0745070A1

  公开（公告）日：1996-12-04
• US5344836A
  申请人：——

  公开号：US5344836A

  公开（公告）日：1994-09-06
• US5891877A
  申请人：——

  公开号：US5891877A

  公开（公告）日：1999-04-06